---
schema_version: "secwatch.filing_event.v1"
accession: "0001799191-23-000020"
form_type: "8-K/A"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:28:02.074334+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman

## Summary
- Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.
- Daniel Virnich, current President, appointed CEO effective June 30, 2023.
- Hively receives salary continuation, COBRA premiums for 12 months, and 50% of 2023 annual bonus at Board discretion.
- All unvested restricted stock units vest through June 30, 2024 per existing vesting schedules.
- Transition was not the result of any disagreement with the Company.

## SEC filing metadata
- accession: 0001799191-23-000020
- form_type: 8-K/A
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/toi-20230608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001799191-23-000020
- JSON: https://secwatch.observer/filing/0001799191-23-000020.json
- Plain text: https://secwatch.observer/filing/0001799191-23-000020.txt

## Key facts
- Executive change
  Brad Hively changed role as Vice Chair of the Board at Oncology Institute, Inc..
  - Action: transitioned
  - Role: Vice Chair of the Board
  source text: Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm
- Executive change
  Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.